Show simple item record

dc.contributor.authorLund, B
dc.contributor.authorRyberg, M
dc.contributor.authorPetersen, P M
dc.contributor.authorAnderson, Heather
dc.contributor.authorThatcher, Nick
dc.contributor.authorDombernowsky, P
dc.date.accessioned2010-07-14T14:20:41Z
dc.date.available2010-07-14T14:20:41Z
dc.date.issued1994-11
dc.identifier.citationPhase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. 1994, 5 (9):852-3 Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.pmid7848889
dc.identifier.urihttp://hdl.handle.net/10541/107634
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntimetabolites, Antineoplastic
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshDeoxycytidine
dc.subject.meshDisease-Free Survival
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLung Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshSurvival Rate
dc.titlePhase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Rigshospitalet, Denmark.en
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record